Prab: CSV import

2025-03-17T10:11:31Z

CSV import

← Older revision		Revision as of 10:11, 17 March 2025
Line 29:		Line 29:
	{{cancer-stub}}		{{cancer-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T16:00:16Z

CSV import

← Older revision		Revision as of 16:00, 10 February 2025
Line 28:		Line 28:
	[[Category:Chemotherapy regimens]]		[[Category:Chemotherapy regimens]]
	{{cancer-stub}}		{{cancer-stub}}
			{{No image}}

Prab: CSV import

2024-03-26T20:40:20Z

CSV import

New page

'''ESHAP''' is a [[chemotherapy]] regimen used for the treatment of [[cancer]], particularly [[Hodgkin lymphoma]] and [[non-Hodgkin lymphoma]]. The acronym ESHAP stands for the drugs that make up the regimen: [[Etoposide]], [[Methylprednisolone]] (Solumedrol), [[Cytarabine]] (Ara-C), and [[Cisplatin]] (Platinol).

==Components==
* '''E'''toposide: A [[topoisomerase inhibitor]] used to disrupt DNA replication in cancer cells.
* '''S'''olumedrol (Methylprednisolone): A [[corticosteroid]] used to reduce inflammation and immune responses.
* '''H'''igh-dose Ara-C (Cytarabine): A [[chemotherapy]] agent that interferes with DNA synthesis.
* '''P'''latinol (Cisplatin): A [[platinum]]-based chemotherapy drug that causes DNA damage.

==Indications==
ESHAP is primarily indicated for patients with relapsed or refractory [[Hodgkin lymphoma]] and [[non-Hodgkin lymphoma]]. It is often considered when the disease does not respond to initial treatments or when there is a relapse after initial remission.

==Mechanism of Action==
Each component of the ESHAP regimen works by a different mechanism to kill cancer cells or slow their growth. Etoposide inhibits the enzyme topoisomerase II, leading to DNA damage. Methylprednisolone acts as an anti-inflammatory and immunosuppressant. Cytarabine is a nucleoside analog that interferes with DNA synthesis, and Cisplatin forms DNA adducts, leading to apoptosis.

==Administration==
ESHAP chemotherapy is typically administered in a hospital setting due to the potential for severe side effects and the need for close monitoring. The regimen is given intravenously over several days in cycles, usually every 3-4 weeks, for a total of 3-6 cycles depending on the patient's response and tolerance to the treatment.

==Side Effects==
The ESHAP regimen, like other chemotherapy treatments, can cause a range of side effects due to its effect on rapidly dividing cells. Common side effects include [[nausea]] and [[vomiting]], [[hair loss]], [[fatigue]], increased risk of [[infection]], and [[myelosuppression]] leading to [[anemia]], [[leukopenia]], and [[thrombocytopenia]]. More severe side effects can include kidney damage (particularly with Cisplatin), and neurological effects.

==Efficacy==
The efficacy of ESHAP varies depending on several factors, including the type and stage of lymphoma, previous treatments, and the overall health of the patient. Studies have shown that ESHAP can be an effective salvage therapy for patients with relapsed or refractory lymphoma, offering a chance for remission in cases where other treatments have failed.

==Conclusion==
ESHAP is an important chemotherapy regimen in the management of relapsed or refractory Hodgkin and non-Hodgkin lymphoma. While it offers hope for patients in difficult situations, the potential for severe side effects requires careful consideration and management by an experienced oncology team.

[[Category:Cancer treatment]]
[[Category:Chemotherapy regimens]]
{{cancer-stub}}

ESHAP - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import